Skip to main content
. 2020 Aug 19;6(8):FSO616. doi: 10.2144/fsoa-2020-0063

Figure 2. . Prevalence of PD-L1 combined positive score ≥1 by tumor type.

Figure 2. 

Analysis included all tumor types. Evaluation of PD-L1 CPS in tissue samples was performed using the PD-L1 IHC 22C3 pharmDx assay (Agilent, CA, USA) and samples with a CPS ≥1 were considered positive.

IHC: Immunohistochemistry; PD-L1 CPS: PD-L1 combined positive score.